Amendment No. 1 to Project Rider #3 Collaboration Agreement between Magenta Therapeutics, Inc. and National Marrow Donor Program d/b/a Be The Match Biotherapies

Contract Categories: Business Operations › Collaboration Agreements
Summary

Magenta Therapeutics, Inc. and the National Marrow Donor Program, operating as Be The Match Biotherapies, have agreed to extend the term of their existing Project Rider #3 under their Collaboration Agreement. This amendment replaces the previous term section with a new end date, allowing the collaboration to continue beyond the original expiration. All other terms of the agreement remain unchanged. The amendment is effective as of the date of the last signature by the authorized representatives of both parties.

Read More Arrow
EX-10.1 2 d814077dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

AMENDMENT #1

TO

PROJECT RIDER #3

COLLABORATION AGREEMENT

This Amendment #1 (“Amendment #1”) is entered into effective as of the date of the final signature executing this Amendment #1 (“Amendment #1 Effective Date”), by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”), (each a “Party” and collectively the “Parties”) as those Parties are defined in Attachment A, Project Rider #3, effective September 6, 2018 (collectively, the “Project Rider #3”).

WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017, and Project Rider #3, effective September 6, 2018; and

WHEREAS, the Parties agree to extend the term of the Project Rider #3.

NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment to be effective as of the Amendment #1 Effective Date as follows:

Amendment to Project Rider #3

 

  1.

Delete the current term in Section D. Term of Project Rider #3 in its entirety and replace it with the following to read as follows:

“The term of this Rider shall commence on the Rider effective date set forth above and continue in effect through [***].”

This Amendment #1 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #1 Effective Date:

 

MAGENTA THERAPEUTICS, INC.     NATIONAL MARROW DONOR PROGRAM d/b/a BE THE MATCH BIOTHERAPIES
By:  

/s/ Angelene Simonello

    By:  

/s/ Mary Frey

  Authorized Signature       Authorized Signature
 

Angelene Simonello

      

Mary Frey

  (Typed/Printed Name)       (Typed/Printed Name)
Title:   VP Program Lead     Title:   Contracts & Procurement Director
Date:   8/26/19     Date:   8/21/19